Treating hyperphosphatemia - current and advancing drugs.

Area of Science:

• Nephrology
• Pharmacology
• Cardiovascular Medicine

Background:

• Hyperphosphatemia is a significant complication in advanced chronic kidney disease (CKD), linked to increased mortality and cardiovascular issues like calcifications.
• Effective phosphate management is crucial for the health and longevity of CKD patients.
• Current management includes phosphate binders, dietary restriction, and intensified dialysis.

Purpose of the Study:

• To review novel phosphate-lowering compounds and strategies for managing hyperphosphatemia in CKD.
• To evaluate emerging therapeutic options, including iron-containing binders and phosphate transport inhibitors.
• To identify gaps in current treatment protocols, such as the optimal timing for intervention.

Main Methods:

• A literature search was conducted using PubMed.
• The search focused on recently approved or in-development phosphate-lowering agents.
• Additional reports on managing resistant hyperphosphatemia were also included.

Main Results:

• Iron-containing phosphate binders show promise with benefits like iron supplementation, reduced pill burden, and high efficacy.
• Phosphate transport inhibitors represent a potential adjunctive therapy for patients not adequately managed with existing binders.
• The optimal stage of CKD for initiating phosphate-lowering interventions remains an open question.

Conclusions:

• Novel iron-based drugs and phosphate transport inhibitors offer new therapeutic avenues for hyperphosphatemia in CKD.
• These agents may improve treatment efficacy and patient adherence.
• Further research is needed to establish the ideal timing for initiating phosphate-lowering therapies in the CKD continuum.